Comparison of Nikkomycin Z Bioavailability Under Fed and Fasting Conditions

NCT ID: NCT01647256

Last Updated: 2013-09-17

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE1
• Total Enrollment: 5 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2012-07-31
• Study Completion Date: 2013-06-30

Brief Summary

The primary purpose of this study is to evaluate if eating a high fat meal versus not eating any food affects how the study drug (Nikkomycin Z) is absorbed into the body. The second purpose is to gain further information about the safety of Nikkomycin Z in healthy adults.

Detailed Description

To compare the single-dose bioavailability of Nikkomycin Z 500 mg (two 250 mg capsules) under fed and fasting conditions.

Conditions

Healthy

Keywords

Bioavailability; Fed; Fasting

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: NONE

Study Groups

Nikkomycin Z fed - fasting

Period 1:

• Day 1: Nikkomycin Z 500 mg with high fat breakfast

Period 2:

• Day 1: Nikkomycin Z 500 mg under fasted conditions

Group Type: EXPERIMENTAL

Nikkomycin Z

Intervention Type: DRUG

Capsule, 500 mg, single-dose

Nikkomycin Z fasting - fed

Period 1:

• Day 1: Nikkomycin Z 500 mg under fasted conditions

Period 2:

• Day 1: Nikkomycin Z 500 mg with high fat breakfast

Group Type: EXPERIMENTAL

Nikkomycin Z

Intervention Type: DRUG

Capsule, 500 mg, single-dose

Interventions

Nikkomycin Z

Capsule, 500 mg, single-dose

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Be at least 18 years of age and not over 40 years of age
• Be male, or female (non childbearing potential or using adequate contraception)
• Have a body mass index between 18 and 29 kg/m2
• Able to understand the study and give written informed consent
• Be determined healthy based on a medical and laboratory evaluation

Exclusion Criteria

• Patients under the age of 18 years or over 40 years of age
• Current smoker or history of smoking within 3 months of participation
• Inability to comprehend study and provide written informed consent
• Inability to comply with the study requirements
• History of or current evidence of major organ disease
• Renal disease - serum creatinine > 1.5 mg/dL, significant hematuria or proteinuria, known structural abnormality or chronic kidney disease
• Hepatic disease - active viral hepatitis, history of hepatitis B or hepatitis C, bilirubin > 2.0, ALT or AST above normal upper limit for laboratory, alcoholic liver disease, other chronic liver disease
• CNS disease or cognitive dysfunction - any past history of epilepsy, CNS infections, stroke, CNS bleed, severe headaches, major psychiatric illness, or current mental status changes
• Lung disease - history of severe asthma, COPD, pulmonary tuberculosis, or other major lung disease
• Cardiac disease - history or current evidence of ischemic coronary artery disease, myocardial infarction, heart failure, or significant arrhythmia
• Gastrointestinal disease - presence of inflammatory bowel disease, difficulty swallowing, or any gastrointestinal probably that would limit taking oral medications or that may compromise absorption of oral medications
• Cancer - History of hematologic malignancy or solid tumor excluding basal cell carcinoma limited to the skin within the past 5 years
• History of autoimmune or inflammatory disease such as rheumatoid arthritis and lupus
• Immunocompromised state - solid organ transplant, cancer chemotherapy, stem cell transplant with graft versus host disease, immunosuppressive therapy, or HIV infection
• Recent weight loss of greater than 10%
• Any other history or evidence of disease that in the opinion of the physician would increase the risk for the subject for clinical trial participation
• Regular use of prescription medications, over-the-counter medications, or dietary/herbal supplements within 14 days of day 1. Occasional use of acetaminophen or over-the-counter NSAID within the 14 day window may be allowed at the P.I. discretion
• Subjects who received another investigational drug within 30 days of enrollment

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 40 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

University of Arizona

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Kathryn R Matthias, PharmD

Role: PRINCIPAL_INVESTIGATOR

University of Arizona

David E Nix, PharmD

Role: PRINCIPAL_INVESTIGATOR

University of Arizona

Locations

University of Arizona - Clinical and Translational Science Research Center

Tucson, Arizona, United States

Countries

United States

Other Identifiers

VFCE-2011-004

Identifier Type: -

Identifier Source: org_study_id